The evolving treatment landscape for patients with headache: what does the future hold?
Mona Nada, MBBCh, MD, Cairo University, Cairo, Egypt, comments on the evolving treatment landscape for migraine and cluster headache. Dr Nada notes that the approval of anti-CGRPs and other migraine-specific treatments has transformed the treatment approach, offering more targeted and effective therapies with fewer side effects. This shift is expected to improve patient outcomes and quality of life. This interview was recorded via an online conference call with The Video Journal of Neurology (VJNeurology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, in my residency in 1989, we didn’t have this at that time, we didn’t have the specific treatment for migraine or for headache. So I think we are in a very important era for headache in general. And especially for migraine, we have drugs that are approved already for the abortive or prophylactic treatment that are migraine-specific. And this change in the landscape of treatment of migraine, including the anti-CGRPs, the PACAP that is just going to be a neurotransmitter now, and maybe in the upcoming years in the future, we will hear more and more as treatments for migraine-specific treatments available...
Well, in my residency in 1989, we didn’t have this at that time, we didn’t have the specific treatment for migraine or for headache. So I think we are in a very important era for headache in general. And especially for migraine, we have drugs that are approved already for the abortive or prophylactic treatment that are migraine-specific. And this change in the landscape of treatment of migraine, including the anti-CGRPs, the PACAP that is just going to be a neurotransmitter now, and maybe in the upcoming years in the future, we will hear more and more as treatments for migraine-specific treatments available. And also for cluster headache. There are ongoing research studies digging into the pathogenesis and trying to have a specific drug used for those patients for cluster headache and other TACs. So in my opinion, the landscape is changing completely within the last five years and that the upcoming future will carry more and more hope for our patients to have more specific treatment with less side effects and higher efficacy, more awareness for the general population and the physicians. So this will help to have more and more patients having proper treatment and less disability and better quality of life.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
